Compare Bristol-Myers Squibb Co (BMY) vs Halliburton Company (HAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Halliburton Company — how do they compare? Bristol-Myers Squibb Co trades at $58.35 (market cap $116.30B), while Halliburton Company trades at $35.05 (market cap $29.59B). The key difference: Bristol-Myers Squibb Co is far larger — about 3.9× Halliburton Company's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | HAL | |
|---|---|---|
Market Cap | $116.30B | $29.59B |
Sector | Health | Energy |
52-Week High | $62.37 | $42.98 |
52-Week Low | $42.60 | $20.50 |
Enterprise Value | $152.24B | $35.67B |
Dividend Yield | 4.42% | 1.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Halliburton (HAL) trades at $35.21, up 2.38% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings beats and a major contract win offshore Suriname highlight operational strength, though net income declined in 2025. The stock shows solid profitability with a 6.95% net margin and 14.56% ROE, supported by positive cash flow trends into 2026.
The outlook remains positive given analyst targets near $44.78 and ongoing energy sector tailwinds, but risks include oil price volatility and execution challenges. Earnings growth and contract execution are key catalysts for further upside, balancing macroeconomic and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →
